Welcome to the June 2017 edition of our newsletter, Updates on Myeloproliferative Neoplasms. In this edition, I'd like to ask you to watch Chapter 7 of the roundtable discussion my colleagues and I recorded, as it focuses on the importance of clinical trials in the advancement of treatments for MPNs.
I’ve also chosen to highlight articles on such topics as the effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis, and the impact of treatments and blood counts on survival and the risk for vascular events during the course of polycythemia vera.
Please share this newsletter with your colleagues, and don’t hesitate to get in touch with me with your comments or suggestions through the editors of the Journal of the Advanced Practitioner in Oncology, or JADPRO, at email@example.com at any time.
Until next time, take a look at the links I’ve gathered for you here. I hope you find this newsletter to be a useful resource in your practice.
Lindsey Lyle, MS, PA-C
University of Colorado, Anschutz Medical Campus